DHAP方案治疗难治性非霍奇金淋巴瘤的疗效观察

Observation of Results of DHAP Regimen in the Treatmant of Refractory Non-Hodgkin's lymphoma

目的观察DHAP联合化疗方案治疗难治性非霍奇金淋巴瘤的疗效及毒性反应。方法DHAP方案包括DDP100mg/m2,静滴,第1d,阿糖胞苷1g/m2,静滴3h,2h重复1次,第1～2d;地塞米松40mg/m2,静滴,第1～4d。3周重复1次,连用2～6周期。结果全组21例难治性非霍奇金淋巴瘤患者接受DHAP方案,CR5例(23.8%),PR7例(33.3%),总有效率57.1%(12/21)。毒副反应主要是白细胞和血小板降率分别是95.2%和38.1%,Ⅲ、Ⅳ度白细胞下降为33.3%、14.3%。Ⅲ～Ⅳ度血小板下降率是19%。结论DHAP方案治疗难治性非霍奇金淋巴瘤疗效较为满意,虽有血液学毒性,但病人均能耐受。

Objective This study is to osbserve the efficacy and txicity of DHAP Combination regime for the patients with refractory non -Hodgkin's lymphoma.Methods Cispcatin100mg /m 2 intra-venous (iv),on day1,cytarabine1g /m 2 iv every12hours on day1to2,dexamethone40mg /m 2 iv on day1to4.All patients received two-six cycles of chemotherapy.Results All21patients with res-fractory non-Hodgkin's lymphoma were treated with DHAP regimen.Overt responses to DHAP were Seen in12patients (57.1%)including5complete responses(CR)(23.8%)and7partial responses(PR)(33.3%).Main toxicity were neutropenia and throm-bocytopenis with occurennce rate of95.2%and38.1%respectively.ⅢtoⅣneutropenia were33.3%and14.3%.ⅢtoⅣthrombocytopenia was19%.Conclusion DHAP regimen in the treatment of refractory non-Hodgkin's lymphoma achieved a sat-isfied results.Though with myelosapprsion,the regi-men is tolerable safely.